Bank of New York Mellon’s scPharmaceuticals SCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-85,292
| Closed | -$484K | – | 4273 |
|
|
2025
Q3 | $484K | Buy |
85,292
+3,834
| +5% | +$19.6K | ﹤0.01% | 3613 |
|
|
2025
Q2 | $310K | Buy |
81,458
+3,311
| +4% | +$10.3K | ﹤0.01% | 3781 |
|
|
2025
Q1 | $206K | Buy |
78,147
+2,973
| +4% | +$9.68K | ﹤0.01% | 3880 |
|
|
2024
Q4 | $266K | Buy |
75,174
+6,051
| +9% | +$23.2K | ﹤0.01% | 3844 |
|
|
2024
Q3 | $315K | Sell |
69,123
-16,978
| -20% | -$82.1K | ﹤0.01% | 3737 |
|
|
2024
Q2 | $375K | Buy |
86,101
+11,269
| +15% | +$49.5K | ﹤0.01% | 3714 |
|
|
2024
Q1 | $376K | Sell |
74,832
-6,698
| -8% | -$37.5K | ﹤0.01% | 3686 |
|
|
2023
Q4 | $511K | Buy |
81,530
+6,674
| +9% | +$38.2K | ﹤0.01% | 3540 |
|
|
2023
Q3 | $533K | Sell |
74,856
-30,156
| -29% | -$238K | ﹤0.01% | 3510 |
|
|
2023
Q2 | $1.07M | Buy |
105,012
+68,827
| +190% | +$718K | ﹤0.01% | 3160 |
|
|
2023
Q1 | $328K | Buy |
36,185
+1,979
| +6% | +$14.5K | ﹤0.01% | 3705 |
|
|
2022
Q4 | $245K | Hold |
34,206
| – | – | ﹤0.01% | 3888 |
|
|
2022
Q3 | $223K | Hold |
34,206
| – | – | ﹤0.01% | 3974 |
|
|
2022
Q2 | $165K | Sell |
34,206
-397
| -1% | -$1.97K | ﹤0.01% | 4120 |
|
|
2022
Q1 | $196K | Sell |
34,603
-40
| -0.1% | -$196 | ﹤0.01% | 4248 |
|
|
2021
Q4 | $173K | Hold |
34,643
| – | – | ﹤0.01% | 4322 |
|
|
2021
Q3 | $230K | Hold |
34,643
| – | – | ﹤0.01% | 4147 |
|
|
2021
Q2 | $211K | Sell |
34,643
-12,034
| -26% | -$72.6K | ﹤0.01% | 4088 |
|
|
2021
Q1 | $310K | Sell |
46,677
-400
| -0.8% | -$2.74K | ﹤0.01% | 3897 |
|
|
2020
Q4 | $249K | Buy |
47,077
+32,639
| +226% | +$256K | ﹤0.01% | 3903 |
|
|
2020
Q3 | $107K | Hold |
14,438
| – | – | ﹤0.01% | 3946 |
|
|
2020
Q2 | $106K | Buy |
+14,438
| New | +$127K | ﹤0.01% | 3905 |
|
|
2019
Q2 | – | Sell |
-20,068
| Closed | -$60K | – | 4269 |
|
|
2019
Q1 | $60K | Sell |
20,068
-100
| -0.5% | -$343 | ﹤0.01% | 4076 |
|
|
2018
Q4 | $76K | Sell |
20,168
-40
| -0.2% | -$188 | ﹤0.01% | 4004 |
|
|
2018
Q3 | $119K | Buy |
20,208
+5,242
| +35% | +$26.7K | ﹤0.01% | 4013 |
|
|
2018
Q2 | $85K | Buy |
14,966
+441
| +3% | +$4.53K | ﹤0.01% | 4023 |
|
|
2018
Q1 | $180K | Sell |
14,525
-19,744
| -58% | -$265K | ﹤0.01% | 3952 |
|
|
2017
Q4 | $414K | Buy |
+34,269
| New | +$484K | ﹤0.01% | 3685 |
|
Bank of New York Mellon's SCPH Position: Q4 2025 in Review
Bank of New York Mellon sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 85,292 shares — an estimated $484K sold.
Bank of New York Mellon first reported a position in SCPH in Q4 2017 and held it in 28 quarters. The position peaked at $1.07M in Q2 2023. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.
- Bank of New York Mellon reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Bank of New York Mellon sold 85,292 scPharmaceuticals shares in Q4 2025, an estimated $484K.
- Bank of New York Mellon first reported a position in scPharmaceuticals in Q4 2017 and held it in 28 quarters.
- Bank of New York Mellon's scPharmaceuticals position peaked at $1.07M in Q2 2023.
- 0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.
Based on Bank of New York Mellon's 13F filing for Q4 2025, filed 10 Feb 2026.